Home/Filings/4/0000950170-25-023584
4//SEC Filing

Young Teresa L. 4

Accession 0000950170-25-023584

CIK 0001609809other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:11 PM ET

Size

13.0 KB

Accession

0000950170-25-023584

Insider Transaction Report

Form 4
Period: 2025-02-15
Young Teresa L.
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-15+2,65793,061 total
  • Exercise/Conversion

    Common Stock

    2025-02-15+7,813100,874 total
  • Sale

    Common Stock

    2025-02-18$0.81/sh3,338$2,70497,536 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-152,65721,250 total
    Common Stock (2,657 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-157,81323,437 total
    Common Stock (7,813 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F3]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.832001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  • [F5]The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Documents

1 file

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001814656

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:11 PM ET
Size
13.0 KB